Phage display screening of therapeutic peptide for cancer targeting and therapy

Abstract

Recently, phage display technology has been announced as the recipient of Nobel Prize in Chemistry 2018. Phage display technique allows high affinity target-binding peptides to be selected from a complex mixture pool of billions of displayed peptides on phage in a combinatorial library and could be further enriched through the biopanning process; proving to be a powerful technique in the screening of peptide with high affinity and selectivity. In this review, we will first discuss the modifications in phage display techniques used to isolate various cancer-specific ligands by in situ, in vitro, in vivo, and ex vivo screening methods. We will then discuss prominent examples of solid tumor targeting-peptides; namely peptide targeting tumor vasculature, tumor microenvironment (TME) and overexpressed receptors on cancer cells identified through phage display screening. We will also discuss the current challenges and future outlook for targeting peptidebased therapeutics in the clinics.

Keywords

phage display / tumor targeting peptide / tumor vasculature / tumor microenvironment / tumor stromal cells / over-expressed receptor

References

[1] Abrahao-Machado LF, Scapulatempo-Neto C (2016) HER2 testing in gastric cancer: an update. World J Gastroenterol 22:4619–4625

[2] Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z (2011) Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol Pharm 8:375–386

[3] Albrecht M, Renneberg H, Wennemuth G, Moschler O, Janssen M, Aumuller G, Konrad L (1999) Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol 112:51–61

[4] AlDeghaither D, Smaglo BG, Weiner LM (2015) Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol 55(Suppl 3):S4–20

[5] Altstock RT, Stein GY, Resau JH, Tsarfaty I (2000) Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. Cytometry 41:155–165

[6] Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R (1997) Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119:227–235

[7] Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380

[8] Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E (2002a) Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 99:1527–1531

[9] Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI (2002b) Steps toward mapping the human vasculature by phage display. Nat Med 8:121–127

[10] Argiris A, Wang CX, Whalen SG, DiGiovanna MP (2004) Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10:1409–1420

[11] Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. Circ Res 97:512–523

[12] Arnold SA, Loomans HA, Ketova T, Andl CD, Clark PE, Zijlstra A (2016) Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis 33:29–44

[13] Augsten M (2014) Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 4:62

[14] Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ (2013) Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum Pathol 44:2028–2037

[15] Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760

[16] Barve A, Jin W, Cheng K (2014) Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release 187:118–132

[17] Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463–475

[18] Benekli M, Baumann H, Wetzler M (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27:4422–4432

[19] Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808–812

[20] Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337

[21] Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541–550

[22] Birkedal-Hansen H (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728–735

[23] Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407

[24] Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR (2012) The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19:3794–3804

[25] Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261

[26] Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802–804

[27] Brinton LT, Bauknight DK, Dasa SS, Kelly KA (2016) PHASTpep: analysis software for discovery of cell-selective peptides via phage display and next-generation sequencing. PLoS ONE 11: e0155244

[28] Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683–693

[29] Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D (2001) The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121:225–233

[30] Burg MA, Pasqualini R, Arap W, Ruoslahti E, Stallcup WB (1999) NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 59:2869–2874

[31] Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353:1652–1654

[32] Chan B, Sinha S, Cho D, Ramchandran R, Sukhatme VP (2005) Critical roles of CD146 in zebrafish vascular development. Dev Dyn 232:232–244

[33] Chang SS, Reuter VE, Heston WD, Gaudin PB (2001) Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 57:1179–1183

[34] Chang DK, Lin CT, Wu CH, Wu HC (2009) A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 4:e4171

[35] Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19:541–555

[36] Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: nextgeneration immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18:6580–6587

[37] Chiquet-Ehrismann R (1990) What distinguishes tenascin from fibronectin? FASEB J 4:2598–2604

[38] Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760

[39] Cieslewicz M, Tang J, Yu JL, Cao H, Zavaljevski M, Motoyama K, Lieber A, Raines EW, Pun SH (2013) Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A 110:15919–15924

[40] Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951

[41] Colvin EK (2014) Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol 4:137

[42] Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33

[43] Denekamp J (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181–196

[44] Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM (1991) Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6:1997–2003

[45] Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA (1992) Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7:2549–2553

[46] Duff SE, Jeziorska M, Rosa DD, Kumar S, Haboubi N, Sherlock D, O’Dwyer ST, Jayson GC (2006) Vascular endothelial growth factors and receptors in colorectal cancer: implications for antiangiogenic therapy. Eur J Cancer 42:112–117

[47] Ebert M, Yokoyama M, Friess H, Buchler MW, Korc M (1994) Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54:5775–5778

[48] Essler M, Ruoslahti E (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 99:2252–2257

[49] Fan M, Liang X, Yang D, Pan X, Li Z, Wang H, Shi B (2016) Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery. J Drug Target 24:111–119

[50] Ferrara N, Alitalo K (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359–1364

[51] Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

[52] Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319:15–26

[53] Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

[54] Fontenot KR, Ongarora BG, LeBlanc LE, Zhou Z, Jois SD, Vicente MG (2016) Targeting of the epidermal growth factor receptor with mesoporphyrin IX–peptide conjugates. J Porphyr Phthalocyanines 20:352–366

[55] Franco OE, Shaw AK, Strand DW, Hayward SW (2010) Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21:33–39

[56] Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Ostling J, Dahan R, Harris RA, Rantalainen M, Klevebring D (2016) Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 15:2000–2011

[57] Gerhardt H, Betsholtz C (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314:15–23

[58] Ghert MA, Jung ST, Qi W, Harrelson JM, Erickson HP, Block JA, Scully SP (2001) The clinical significance of tenascin-C splice variant expression in chondrosarcoma. Oncology 61:306–314

[59] Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG (2008) High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 39:1835–1843

[60] Giordano RJ, Cardo-Vila M, Lahdenranta J, Pasqualini R, Arap W (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249–1253

[61] Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S (1994) Highaffinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A 91:7129–7133

[62] Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37–46

[63] Green CL, Loken M, Buck D, Deeg HJ (2000) Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML). Leukemia 14:770–772

[64] Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55–62

[65] Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, Chen Y, Zhu H, Magi-Galluzzi C, Lu ZR (2015) EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug Chem 26:830–838

[66] Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364

[67] Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T (1997) Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 73:10–15

[68] Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, Piercecchi-Marti MD, Berenguer C, Lamy E, Vely F, Pisano P (2010) Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115:3843–3851

[69] Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121:938–942

[70] Hashida M, Nishikawa M, Yamashita F, Takakura Y (2001) Cellspecific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 52:187–196

[71] Hayashi MA, Ducancel F, Konno K (2012) Natural peptides with potential applications in drug development, diagnosis, and/or biotechnology. Int J Pept 2012:757838

[72] He C, Su S, Chen F, Huang D, Zheng F, Huang W, Chen J, Cui X, Liu Q, Song E (2014) Overexpression of PITPNM3 promotes hepatocellular carcinoma cell metastasis. Chin Sci Bull 59:1326–1333

[73] Hellstrom I, Beaumier PL, Hellstrom KE (1986a) Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A 83:7059–7063

[74] Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE (1986b) Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 46:3917–3923

[75] Hemesath TJ, Stefansson K (1994) Expression of tenascin in thymus and thymic nonlymphoid cells. J Immunol 152:422–428

[76] Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178–15183

[77] Henderson GB (1990) Folate-binding proteins. Annu Rev Nutr 10:319–335

[78] Heppeler A, Froidevaux S, Eberle AN, Maecke HR (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7:971–994

[79] Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323

[80] Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H (1999) Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 189:475–480

[81] Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580

[82] Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D (1999) Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 93:1435–1437

[83] Houimel M, Schneider P, Terskikh A, Mach JP (2001) Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int J Cancer 92:748–755

[84] Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386–396

[85] Huntsman D, Resau JH, Klineberg E, Auersperg N (1999) Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 155:343–348

[86] Inufusa H, Nakamura M, Adachi T, Nakatani Y, Shindo K, Yasutomi M, Matsuura H (1995) Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer 75:2802–2808

[87] Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38:2362–2370

[88] Jain RK (2001) Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46:149–168

[89] Jeon H, Kim D, Choi M, Kang S, Kim JY, Kim S, Jon S (2017) Targeted Cancer Therapy Using Fusion Protein of TNFalpha and Tumor-Associated Fibronectin-Specific Aptide. Mol Pharm 14:3772–3779

[90] Jin W, Qin B, Chen Z, Liu H, Barve A, Cheng K (2016) Discovery of PSMA-specific peptide ligands for targeted drug delivery. Int J Pharm 513:138–147

[91] Jung W, Castren E, Odenthal M, Vande Woude GF, Ishii T, Dienes HP, Lindholm D, Schirmacher P (1994) Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol 126:485–494

[92] Jyothi T (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:13

[93] Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T, Watanabe G (2001) The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 85:255–260

[94] Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321–5325

[95] Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428

[96] Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401

[97] Kane MA, Elwood PC, Portillo RM, Antony AC, Najfeld V, Finley A, Waxman S, Kolhouse JF (1988) Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 81:1398–1406

[98] Kang Y, Wang F, Feng J, Yang D, Yang X, Yan X (2006) Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res 16:313–318

[99] Karasseva NG, Glinsky VV, Chen NX, Komatireddy R, Quinn TP (2002) Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J Protein Chem 21:287–296

[100] Kaspar M, Zardi L, Neri D (2006) Fibronectin as target for tumor therapy. Int J Cancer 118:1331–1339

[101] Kebir A, Harhouri K, Guillet B, Liu JW, Foucault-Bertaud A, Lamy E, Kaspi E, Elganfoud N, Vely F, Sabatier F (2010) CD146 short isoform increases the proangiogenic potential of endothelial progenitor cells in vitro and in vivo. Circ Res 107:66–75

[102] Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119:243–250

[103] Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R (2005) Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96:327–336

[104] Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13:31–36

[105] Khan ZA, Caurtero J, Barbin YP, Chan BM, Uniyal S, Chakrabarti S (2005) ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res 31:701–711

[106] Kim MY, Kim OR, Choi YS, Lee H, Park K, Lee CT, Kang KW, Jeong S (2012a) Selection and characterization of tenascin C targeting peptide. Mol Cells 33:71–77

[107] Kim S, Kim D, Jung HH, Lee IH, Kim JI, Suh JY, Jon S (2012b) Bioinspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew Chem Int Ed Engl 51:1890–1894

[108] Kim H, Lee Y, Lee IH, Kim S, Kim D, Saw PE, Lee J, Choi M, Kim YC, Jon S (2014) Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. J Control Release 178:118–124

[109] Kim H, Lee Y, Kang S, Choi M, Lee S, Kim S, Gujrati V, Kim J, Jon S (2016) Self-assembled nanoparticles comprising aptide-SN38 conjugates for use in targeted cancer therapy. Nanotechnology 27:48LT01

[110] Klein G, Beck S, Muller CA (1993) Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment. J Cell Biol 123:1027–1035

[111] Koivunen E, Wang B, Ruoslahti E (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13:265–270

[112] Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774

[113] Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088–3095

[114] Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, Weaver DL, Burdette-Radoux S, Thomas C (2006) Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res 66:7724–7733

[115] Kumar R, Mandal M, Lipton A, Harvey H, Thompson CB (1996) Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifeninduced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2:1215–1219

[116] Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167:e211–e219

[117] Kwon MK, Nam JO, Park RW, Lee BH, Park JY, Byun YR, Kim SY, Kwon IC, Kim IS (2008) Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3. Mol Cancer Ther 7:1514–1522

[118] Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E (2002) A tumorhoming peptide with a targeting specificity related to lymphatic vessels. Nat Med 8:751–755

[119] Landon LA, Deutscher SL (2003) Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 90:509–517

[120] Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC (2007) Peptidemediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67:10958–10965

[121] Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878–5887

[122] Lehmann JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 86:9891–9895

[123] Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, Xu Y, Gu J (2005) Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19:1978–1985

[124] Li J, Wang H, Li J, Bao J, Wu C (2016) Discovery of a potential HER2 inhibitor from natural products for the treatment of HER2-Positive Breast cancer. Int J Mol Sci 17:E1055

[125] Li C, Zhang N, Zhou J, Ding C, Jin Y, Cui X, Pu K, Zhu Y (2018) Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunol Res 6:178–188

[126] Lin WJ, Kao LT (2014) Cytotoxic enhancement of hexapeptideconjugated micelles in EGFR high-expressed cancer cells. Expert Opin Drug Deliv 11:1537–1550

[127] Lindgren M, Rosenthal-Aizman K, Saar K, Eiriksdottir E, Jiang Y, Sassian M, Ostlund P, Hallbrink M, Langel U (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71:416–425

[128] Liu X, Peng J, He J, Li Q, Zhou J, Liang X, Tang S (2018) Selection and identification of novel peptides specifically targeting human cervical cancer. Amino Acids 50:577–592

[129] Lo A, Lin CT, Wu HC (2008) Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7:579–589

[130] Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120–129

[131] Lyons AJ, Bateman AC, Spedding A, Primrose JN, Mandel U (2001) Oncofetal fibronectin and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 39:471–477

[132] Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14:399–416

[133] Margus H, Padari K, Pooga M (2012) Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 20:525–533

[134] Marken JS, Schieven GL, Hellstrom I, Hellstrom KE, Aruffo A (1992) Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A 89:3503–3507

[135] Marqus S, Pirogova E, Piva TJ (2017) Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 24:21

[136] Matsue H, Rothberg KG, Takashima A, Kamen BA, Anderson RG, Lacey SW (1992) Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc Natl Acad Sci U S A 89:6006–6009

[137] Medrek C, Ponten F, Jirstrom K, Leandersson K (2012) The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12:306

[138] Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799

[139] Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E (2017) Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Med Oncol 34:91

[140] Mhawech P, Dulguerov P, Assaly M, Ares C, Allal AS (2005) EB-D fibronectin expression in squamous cell carcinoma of the head and neck. Oral Oncol 41:82–88

[141] Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701–708

[142] Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021

[143] Morris MC, Depollier J, Mery J, Heitz F, Divita G (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–1176

[144] Naidoo J, Page DB, Wolchok JD (2014) Immune Checkpoint Blockade. Hematol Oncol Clin North Am 28:585–600

[145] Ndinguri MW, Bhowmick M, Tokmina-Roszyk D, Robichaud TK, Fields GB (2012) Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules 17:14230–14248

[146] Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ (2007) Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 355:855–859

[147] Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB (1996) Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neurosci Res 43:315–330

[148] O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110

[149] Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167

[150] Ongarora BG, Fontenot KR, Hu X, Sehgal I, Satyanarayana-Jois SD, Vicente MG (2012) Phthalocyanine-peptide conjugates for epidermal growth factor receptor targeting. J Med Chem 55:3725–3738

[151] O’Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926–1928

[152] Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, Abdraboh ME, El-Sayyad HI, Rao P, Raj MG (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795:130–136

[153] Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

[154] Park J, Kim S, Saw PE, Lee IH, Yu MK, Kim M, Lee K, Kim YC, Jeong YY, Jon S (2012) Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. J Control Release 163:111–118

[155] Park J, Park S, Kim S, Lee I-H, Saw PE, Lee K, Kim Y-C, Kim Y-J, Farokhzad OC, Jeong YY (2013) HER2-specific aptide conjugated magneto-nanoclusters for potential breast cancer imaging and therapy. J Mater Chem B 1:4576–4583

[156] Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364–366

[157] Pasqualini R, Koivunen E, Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15:542–546

[158] Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722–727

[159] Prewett M, Huber J, Li Y, Santiago A, O’Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209–5218

[160] Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H (2001) Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129–135

[161] Pupa SM, Menard S, Forti S, Tagliabue E (2002) New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 192:259–267

[162] Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH (2002) Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62:589–596

[163] Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102:430–437

[164] Rasanen K, Vaheri A (2010) Activation of fibroblasts in cancer stroma. Exp Cell Res 316:2713–2722

[165] Ren H, Gao C, Zhou L, Liu M, Xie C, Lu W (2015) EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation. Drug Deliv 22:785–794

[166] Ribeiro AL, Okamoto OK (2015) Combined effects of pericytes in the tumor microenvironment. Stem Cells Int 2015:868475

[167] Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115

[168] Rimawi MF, Schiff R, Osborne CK (2015) Targeting HER2 for the treatment of breast cancer. Annu Rev Med 66:111–128

[169] Rizzo S, Attard G, Hudson DL (2005) Prostate epithelial stem cells. Cell Prolif 38:363–374

[170] Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF (1993) Met expression and sarcoma tumorigenicity. Cancer Res 53:5355–5360

[171] Rong S, Segal S, Anver M, Resau JH, Vande Woude GF (1994) Invasiveness and metastasis of NIH 3T3 cells induced by Methepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A 91:4731–4735

[172] Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H, Colomer R (2004) Trastuzumab plus tamoxifen: antiproliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86:125–137

[173] Ross JF, Chaudhuri PK, Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73:2432–2443

[174] Rouleau C, Gianolio DA, Smale R, Roth SD, Krumbholz R, Harper J, Munroe KJ, Green TL, Horten BC, Schmid SM (2015) Antiendosialin antibody–drug conjugate: potential in sarcoma and other malignancies. Mol Cancer Ther 14:2081–2089

[175] Ruoslahti E (2000) Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:435–442

[176] Ruoslahti E (2003) The RGD story: a personal account. Matrix Biol 22:459–465

[177] Ruoslahti E (2004) Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 32:397–402

[178] Ruoslahti E (2012) Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater 24:3747–3756

[179] Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637–650

[180] Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G (2003) Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82:147–154

[181] Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182:389–400

[182] Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, Hirschi KK, Davis GE (2006) Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 175:179–191

[183] Saw PE, Kim S, Lee I-H, Park J, Yu M, Lee J, Kim J-I, Jon S (2013) Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J Mater Chem B 1:4723–4726

[184] Saw PE, Park J, Lee E, Ahn S, Lee J, Kim H, Kim J, Choi M, Farokhzad OC, Jon S (2015) Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Theranostics 5:746–754

[185] Saw PE, Park J, Jon S, Farokhzad OC (2017) A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. Nanomedicine 13:713–722

[186] Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ (1990) Expression of the high molecular weight melanomaassociated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136:1393–1405

[187] Segers FM, Yu H, Molenaar TJ, Prince P, Tanaka T, van Berkel TJ, Biessen EA (2012) Design and validation of a specific scavenger receptor class AI binding peptide for targeting the inflammatory atherosclerotic plaque. Arterioscler Thromb Vasc Biol 32:971–978

[188] Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31

[189] Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H (2015) Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 7:2443–2458

[190] Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, Brown LF, Dvorak HF (2009) The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res 69:3272–3277

[191] Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828

[192] Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401

[193] Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317

[194] Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100

[195] Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, Xu Y (2008) Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 363:155–161

[196] Song S, Liu D, Peng J, Deng H, Guo Y, Xu LX, Miller AD, Xu Y (2009) Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 23:1396–1404

[197] Sorensen MD, Kristensen P (2011) Selection of antibodies against a single rare cell present in a heterogeneous population using phage display. Nat Protoc 6:509–522

[198] Stapor PC, Sweat RS, Dashti DC, Betancourt AM, Murfee WL (2014) Pericyte dynamics during angiogenesis: new insights from new identities. J Vasc Res 51:163–174

[199] Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, Chou CH, Hu CL, Kuo ML, Hsieh CY (2005) A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res 65:4827–4835

[200] Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F (2018) CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172:841–856.e816

[201] Suer S, Sonmez H, Karaaslan I, Baloglu H, Kokoglu E (1996) Tissue sialic acid and fibronectin levels in human prostatic cancer. Cancer Lett 99:135–137

[202] Sun J, Zhang C, Liu G, Liu H, Zhou C, Lu Y, Zhou C, Yuan L, Li X (2012) A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro. Clin Exp Metastasis 29:185–196

[203] Suzuki H, Sasada M, Kamiya S, Ito Y, Watanabe H, Okada Y, Ishibashi K, Iyoda T, Yanaka A, Fukai F (2017) The promoting effect of the extracellular matrix peptide TNIIIA2 derived from tenascin-C in colon cancer cell infiltration. Int J Mol Sci 18:E181

[204] Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998) Prostatespecific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640

[205] Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94:701–706

[206] Tang C, Ang BT, Pervaiz S (2007) Cancer stem cell: target for anticancer therapy. FASEB J 21:3777–3785

[207] Tsunoda T, Inada H, Kalembeyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T (2003) Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 162:1857–1867

[208] Tu T, Zhang C, Yan H, Luo Y, Kong R, Wen P, Ye Z, Chen J, Feng J, Liu F (2015) CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res 25:275–287

[209] Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571

[210] Ujula T, Huttunen M, Luoto P, Peräkylä H, Simpura I, Wilson I, Bergman M, Roivainen A (2010) Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjug Chem 21:1612–1621

[211] Vauquelin G, Charlton SJ (2013) Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol 168:1771–1785

[212] Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O’Donnell CJ (2015) Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Mol Cancer Ther 14:1868–1876

[213] Waller CF, Martens UM, Lange W (1999) Philadelphia chromosomepositive cells are equally distributed in AC133+ and AC133-fractions of CD34+ peripheral blood progenitor cells from patients with CML. Leukemia 13:1466–1467

[214] Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330:150–162

[215] Wang J, Masehi-Lano JJ, Chung EJ (2017) Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci 5:1450–1459

[216] Wells A (1999) EGF receptor. Int J Biochem Cell Biol 31:637–643

[217] Wernert N (1997) The multiple roles of tumour stroma. Virchows Arch 430:433–443

[218] Wierzbicka-Patynowski I, Schwarzbauer JE (2003) The ins and outs of fibronectin matrix assembly. J Cell Sci 116:3269–3276

[219] Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28

[220] Wu CH, Liu IJ, Lu RM, Wu HC (2016) Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci 23:8

[221] Wulfing P, Kersting C, Buerger H, Mattsson B, Mesters R, Gustmann C, Hinrichs B, Tio J, Bocker W, Kiesel L (2005) Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92:1720–1728

[222] Xiao J, Burn A, Tolbert TJ (2008) Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjug Chem 19:1113–1118

[223] Xing L, Xu Y, Sun K, Wang H, Zhang F, Zhou Z, Zhang J, Zhang F, Caliskan B, Qiu Z (2018) Identification of a peptide for folate receptor alpha by phage display and its tumor targeting activity in ovary cancer xenograft. Sci Rep 8:8426

[224] Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102:184–191

[225] Yang H, Liu S, Cai H, Wan L, Li S, Li Y, Cheng J, Lu X (2010) Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem 285:25666–25676

[226] Yang F, Ai W, Jiang F, Liu X, Huang Z, Ai S (2016) Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: toxicity, Biodistribution, and Efficacy in Mice. J Pharm Sci 105:639–649

[227] Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137

[228] Ye Z, Zhang C, Tu T, Sun M, Liu D, Lu D, Feng J, Yang D, Liu F, Yan X (2013) Wnt5a uses CD146 as a receptor to regulate cell motility and convergent extension. Nat Commun 4:2803

[229] Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012

[230] Yu D, Hung MC (2000) Role of erbB2 in breast cancer chemosensitivity. BioEssays 22:673–680

[231] Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51

[232] Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809

[233] Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, Smith CA, Yull FE, Duvall CL, Giorgio TD (2013) Macrophage-specific RNA interference targeting via “click”, mannosylated polymeric micelles. Mol Pharm 10:975–987

[234] Yue P, Turkson J (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 18:45–56

[235] Zanini E, Louis LS, Antony J, Karali E, Okon IS, McKie AB, Vaughan S, El-Bahrawy M, Stebbing J, Recchi C (2017) The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Mol Cancer Ther 16:2246–2256

[236] Zhang Q, Tang J, Fu L, Ran R, Liu Y, Yuan M, He Q (2013) A pHresponsive alpha-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34:7980–7993

[237] Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, Hudson E, Resau J, Gross M, Vande Woude GF (2007) Identification of a met-binding peptide from a phage display library. Clin Cancer Res 13:6049–6055

[238] Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D, Yang D, Feng J, Yan X (2009) Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 41:2163–2172

[239] Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol 17:170–182

[240] Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4

[241] Zurita AJ, Arap W, Pasqualini R (2003) Mapping tumor vascular diversity by screening phage display libraries. J Control Release 91:183–186

RIGHTS & PERMISSIONS

2019 The Author(s)